Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Retinal Disease: early-phase trial registry
14 of 20 indexed Retinal Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #848 of 28,707 conditions by registered trial count.
20 US clinical trials · 14 currently recruiting · #848 of 28,707 conditions by registered trial count
Retinal Disease: 20 US clinical trials tracked, 14 recruiting.
Retinal Disease is the subject of 20 registered US clinical trials on ClinicalTrials.gov, 14 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is National Eye Institute (NEI), running 3 of these trials.
Enrollment posture brief
Registry condition retinal-disease
OPEN 14 | RECR 70% | LATE 1 | EARLY 5 | RANK #848 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Advanced Solid Tumor (70% recruiting · 190 trials)
Retinal Disease lists 14 open slots (70% of 20 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Retinal Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Retinal Disease is recruiting above its size-band peers.
14 of 20 indexed trials (70%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Retinal Disease research.
National Eye Institute (NEI) accounts for 3 of 20 trials (15%). 13 distinct sponsors appear on at least one study for this condition label.
-
Typical Retinal Disease enrolment sits around 81 participants.
Median target enrolment is 81 among the 20 trials that report a genuine target (sentinel values excluded). 11 of those (55%) plan for fewer than 100 participants.
-
Retinal Disease splits between interventional and observational designs.
9 interventional and 11 observational studies make up this index (45% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
20 total, page 1 of 1
Inherited Retinal Degenerative Disease Registry
Foundation Fighting Blindness
NCT02435940
Cell Collection to Study Eye Diseases
National Eye Institute (NEI)
NCT01432847
National Eye Institute Biorepository for Retinal Diseases
National Eye Institute (NEI)
NCT01496625
Stem Cell Ophthalmology Treatment Study II
MD Stem Cells
NCT03011541
Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene
National Eye Institute (NEI)
NCT01145196
Intraoperative OCT Guidance of Intraocular Surgery II
Duke University
NCT03713268
Data Gathering for A10900
Optos
NCT07149740
P200TxE Diseased Eye Image Collection
Optos
NCT06269666
Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
Laboratoires Thea
NCT06627179
COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Inherited Retinal Disease
University of Wisconsin, Madison
NCT06380075
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
Laboratoires Thea
NCT06891443
Optimize Pediatric OCT Imaging
Duke University
NCT06139523
A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
PYC Therapeutics
NCT06852963
MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)
PYC Therapeutics
NCT06455826
Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study
Complement Therapeutics
NCT05797896
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)
ProQR Therapeutics
NCT03913143
A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene
ProQR Therapeutics
NCT04123626
Stem Cell Models of Best Disease and Other Retinal Degenerative Diseases.
Mayo Clinic
NCT02162953
Topcon 3D OCT-1000 Optical Coherence Tomography System
Topcon Medical Systems
NCT00792259
Natural History Study of CEP290-Related Retinal Degeneration
Editas Medicine
NCT03396042
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Retinal Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Retinal Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Retinal Disease page
20 registered trials, 14 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 14 Retinal Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Eye Institute (NEI) sponsors the most Retinal Disease trials on record, review their full trial history before evaluating a specific study. See National Eye Institute (NEI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Retinal Disease condition card totals 20 registered trials; most-linked intervention VP-001; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.